Germany · Delayed Price · Currency is EUR HLS Therapeutics Company Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally.
The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A.
HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
| Country | Canada |
| Industry | Pharmaceutical Preparations |
| Employees | 92 |
| CEO | Craig Millian |
Contact Details
Address: 10 Carlson Court Etobicoke, Ontario M9W 6L2 Canada | |
| Phone | 647 495 9000 |
| Website | hlstherapeutics.com |
Stock Details
| Ticker Symbol | 74D |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig Millian | Chief Executive Officer |
| John Hanna | Chief Financial Officer |
| Dave Mason | Head of Investor Relations |